Industry Experts blogging about Dry Eye Disease
Many times we must decide how to treat chronic blepharitis patients. While many times patients are managed well with topical Azithromycin both on initial presentation as well longer term treatment. However when their is significant inflammation involved, Tobramycin combined with dexamethasone can give significant relief to the … [Read more...]
New technology may objectively confirm patients’ subjective dry eye symptoms Tear osmolarity measurements may provide a biomarker of dry eye severity. Optometrists are finding that a new in-office diagnostic technology from TearLab Corp. helps guide their dry eye treatment regimen and improves patient … [Read more...]
Tokyo, Japan, November 9, 2010 In a press release, Otsuka Pharmaceutical Co., Ltd. today announced it has applied for regulatory approval in Japan to manufacture and market Mucosta® (rebamipide) ophthalmic suspension for treatment of dry eye. By its novel mechanism of action to promote the production of mucin in the ocular … [Read more...]
In my initial work with the TearLab, I have been very impressed and encouraged by the ease of use and consistent findings. I expect that this technology will help me provide better care for my patients, particularly those with ocular surface disease. We are currently conducting a study to determine the relationship between … [Read more...]
A series from Science Based Health http://www.visioncareprofessional.com/emails/SBH/2/index.asp Tip #1: Be knowledgeable and confident about the clinical research around dry eye and nutrition. There are numerous studies specifically on dry eye and nutrition. Some omega fatty acids have been clinically shown to help … [Read more...]
Korb DR, Blackie CA. Korb Associates, Boston, MA, USA. Abstract A new and previously unpublished thermodynamic treatment device, which for the first time applies heat directly to both inner eyelid surfaces with a precision-controlled resistive heater while pulsating pressure is simultaneously applied to the outer eyelids … [Read more...]
Restasis® (Cyclosporine Ophthalmic Emulsion 0.05% - Allergan, Inc.) is an immunosuppressive agent when administered systemically. In patients whose tear production is decreased due to ocular inflammation associated with keratoconjunctivitis sicca (Dry Eye Disease - DED), cyclosporine emulsion is thought to act as a partial … [Read more...]
Patients presenting with dry eye disease commonly are prescribed artificial tears or eye drops as an initial course of therapy. Treatment efficacy is often based on improvement in symptoms, as reported subjectively by the patient. Unfortunately it is well known that symptoms do not correlate with objective signs of dry eye … [Read more...]
A look at new classifications as well as diagnosis and treatment options for this prevalent disease. A contact lens spectrum article by Blair B. Lonsberry, MS, OD, MEd, FAAO http://www.clspectrum.com/article.aspx?article=104449 … [Read more...]
